DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1,  a self-developed and ...

such as resistance to EGFR-targeted therapies, endocrine therapy in breast cancer, HER2-targeted therapies, and chemotherapy. Injectable AK138D1 is a HER3-targeted antibody-drug conjugate (ADC ...

BL-B01D1 recognizes EGFR and HER3 5. Image Credit: Sino Biological Inc. An example of this is the BsADC design targeting HER2×CD63. As HER2's resistance to internalization may reduce drug ...

The HER3-directed ADC will be tested in patients whose disease had progressed despite earlier treatment with EGFR inhibitors, including third-generation drugs like AZ's Tagrisso (osimertinib).

Objectives HER3 is a receptor tyrosine kinase that forms heterodimers with HER2 and EGFR and plays an important role in the pro-oncogenic signaling pathways of HER2+ breast cancer. We developed an ...

The YL202/BNT326 is a novel antibody-drug conjugate ADC designed by BioNTech to target HER3, combining an anti-HER3 ... patients bearing EGFR-activating mutations, as well as HR-positive, ...